MicroRNAs in the context of human diseases
Sonkoly E
Journal of Translational Medicine · 2010
doi:10.1186/1479-5876-8-s1-i8 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The discovery of microRNAs is one of the major scientific breakthroughs in recent years and has revolutionized the way we look at gene regulation. MicroRNAs are small non-coding RNAs that regulate the expression of protein-coding genes via posttranscriptional suppression. Each microRNA can regulate dozens to hundreds of genes, making their regulatory potential enormous. MicroRNAs regulate basic biological processes and have been implicated in the development of the immune system as well as in immune responses. In line with their essential role in physiological processes, deregulation of microRNAs has been linked to human diseases. MicroRNAs are frequently deregulated in cancers. In the past few years, dozens of microRNAs were identified, which act as tumor suppressors or oncogens and regulate carcinogenesis, tumor progression and metastasis. Recently, deregulation of microRNAs has been shown in chronic inflammatory and immune-mediated diseases such as psoriasis, atopic dermatitis, rheumatoid arthritis and systemic lupus erythematosus. However, we are still at the beginning in understanding their roles in the regulation of inflammatory pathways and the pathogenesis of inflammatory diseases. Since microRNA levels can be modulated by introducing microRNA mimics and inhibitors to the cells, we predict that overexpression or suppression of microRNA levels may become a novel therapeutic approach in the treatment of cancer and inflammatory diseases in the future.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.